Recently, Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore), a subsidiary of  YOUNGY GROUP, independently developed the bispecific nanobody drug RC1416 injection, which has been approved for clinical trials by the US Food and Drug Administration (FDA), marking the synchronization of the product's clinical development strategy with the international market. RC1416 is a recombinant anti human IL-4Ra and IL-5 single domain antibody injection that has been approved for clinical trials by the National Drug Administration on March 27 this year, with additional maintenance therapy for moderate to severe asthma as the indication.

RegeneCore is a leading innovative high-tech enterprise of YOUNGY GROUP in the field of nanobody medicine in China, committed to the research and development of innovative biological drugs of nanobody technology. At present, innovative research and development have been carried out for autoimmune diseases, tumors, etc., as well as research on coupling drugs and cell therapy products based nanobody.